JP2023537675A5 - - Google Patents

Info

Publication number
JP2023537675A5
JP2023537675A5 JP2023503426A JP2023503426A JP2023537675A5 JP 2023537675 A5 JP2023537675 A5 JP 2023537675A5 JP 2023503426 A JP2023503426 A JP 2023503426A JP 2023503426 A JP2023503426 A JP 2023503426A JP 2023537675 A5 JP2023537675 A5 JP 2023537675A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
months
group
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057474 external-priority patent/WO2022038475A1/en
Publication of JP2023537675A publication Critical patent/JP2023537675A/ja
Publication of JP2023537675A5 publication Critical patent/JP2023537675A5/ja
Pending legal-status Critical Current

Links

JP2023503426A 2020-08-17 2021-08-13 パーキンソン病の治療のための医薬組成物及びその治療方法 Pending JP2023537675A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063066386P 2020-08-17 2020-08-17
US63/066,386 2020-08-17
US202163229021P 2021-08-03 2021-08-03
US63/229,021 2021-08-03
PCT/IB2021/057474 WO2022038475A1 (en) 2020-08-17 2021-08-13 Pharmaceutical compositions and methods for treating parkinson's disease

Publications (2)

Publication Number Publication Date
JP2023537675A JP2023537675A (ja) 2023-09-05
JP2023537675A5 true JP2023537675A5 (enExample) 2024-08-20

Family

ID=80223734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023503426A Pending JP2023537675A (ja) 2020-08-17 2021-08-13 パーキンソン病の治療のための医薬組成物及びその治療方法
JP2023501570A Pending JP2023537840A (ja) 2020-08-17 2021-08-13 ナビロンを単独及びカンナビノイドと併用する経皮製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023501570A Pending JP2023537840A (ja) 2020-08-17 2021-08-13 ナビロンを単独及びカンナビノイドと併用する経皮製剤

Country Status (8)

Country Link
US (3) US20220047541A1 (enExample)
EP (2) EP4196114A4 (enExample)
JP (2) JP2023537675A (enExample)
CN (2) CN115884761A (enExample)
AU (2) AU2021328741A1 (enExample)
CA (2) CA3187588A1 (enExample)
MX (2) MX2023000314A (enExample)
WO (2) WO2022038479A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
EP4046630A1 (en) * 2021-02-18 2022-08-24 LTS Lohmann Therapie-Systeme AG Tts-formulation with thc
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2022260813A1 (en) * 2021-04-22 2023-10-26 Pike Therapeutics Inc. Transdermal pharmaceutical formulations for the treatment of chronic pain
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
GB202206000D0 (en) * 2022-04-25 2022-06-08 Univ Stellenbosch Leonotis leonurus extracts as a chemoprotectant and post-chemotherapeutic agent
US20240024253A1 (en) * 2022-07-21 2024-01-25 Pike Therapeutics Inc. Continuous Drug Delivery Systems and Methods
CN116077419B (zh) * 2023-02-24 2023-10-27 丽珠集团新北江制药股份有限公司 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation
CN116617161B (zh) * 2023-07-26 2023-10-24 中国科学院理化技术研究所 一种包含大麻二酚混悬液的可溶性微针及其制备方法
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6617356B2 (en) * 2000-01-03 2003-09-09 Naturally Scientific Inc Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2008006226A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2476414B1 (en) * 2009-09-07 2015-03-04 NIPRO Patch Co., Ltd. Transdermally absorbable preparation
BR112013001422A2 (pt) * 2010-07-20 2019-09-24 Phytopharm Plc metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3509585B1 (en) * 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
JP7225103B2 (ja) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
CA3064782A1 (en) * 2017-05-26 2018-11-29 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
EP3678647A1 (en) * 2017-09-05 2020-07-15 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of rivastigmine
JOP20200045A1 (ar) * 2017-09-19 2020-02-27 Zynerba Pharmaceuticals Inc كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
US11141172B2 (en) * 2018-04-11 2021-10-12 Globus Medical, Inc. Method and apparatus for locking a drill guide in a polyaxial hole
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
US11660283B2 (en) * 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
EP3906025A4 (en) * 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
US10842758B1 (en) * 2019-06-18 2020-11-24 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations containing cannabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
TWI298254B (en) Use of optically pure (s,s) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
JP7378781B2 (ja) 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療
EP2666356A1 (en) Rasagiline for parkinson's disease modification
JP2008519847A (ja) 運動障害の治療方法
TW202339764A (zh) 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
CA2667924A1 (en) The use of pramipexole or a salt thereof for the treatment of parkinson's disease
US20260077192A1 (en) Combination therapy for the treatment of depression
TW200831097A (en) Treatment of anxiety with eszopiclone
CN115279356A (zh) 认知障碍预防和治疗
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
KR20150110829A (ko) 약제학적 제제 및 여성 성기능장애의 치료에서 이의 용도
Rajeswari Prosthodontic considerations in Parkinson’s disease
RU2428164C2 (ru) Способ лечения табачной зависимости у мужчин
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
EP4618973A1 (en) Methods of switching neuropsychiatric medications using ulotaront
Rizek et al. Management of Advanced Parkinson’s Disease
AU2023266335A1 (en) Composition for improving sleep
TW202313017A (zh) 治療自發性震顫的方法
Vinogradov et al. Insomnia and Sleep-Related Breathing Disorders: New Risk Factors for Ischemic Stroke
Spiegelhalder et al. 24 in the elderly
Fang Update on the medical management of Parkinson disease
JP2007511577A (ja) （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用
Kojima et al. Treatment with L‐DOPA in Two Cases of Organic Brain Syndrome
Ciucci The effects of deep brain stimulation on deglutition in Parkinson Disease
Mahant, N., Fung, VS & Morris Assessing and managing Parkinson's disease